TIEFENBACHER GROUP and OnDosis are thrilled to announce the launch of OYSTA®. The new healthcare brand represents the cooperation initiated in September 2020, including the co-development portfolio of innovative products in five indications. OYSTA® aims to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and
OnDosis, ett svenskt medicinteknikbolag som utvecklar en unik device-plattform för flexibel och individanpassad dosering av läkemedel, och Stardots, ett svenskt digitalt hälsobolag som utvecklar produkter inom neurologi, meddelar idag att bolagen ingått ett strategiskt samarbete. Avsikten är att kombinera bolagens banbrytande teknologier för att möjliggöra utveckling av unika produkter för beh
OnDosis, a Swedish Life science company developing a new drug/device technology platform, announced today that the Company has completed a private placement of SEK 75 million. Investors in the private placement include OnDosis founders AstraZeneca and Martin Olovsson and major shareholders Aeternum Capital, DIG Investment and Rydgruppen
Aktieägarna i OnDosis AB, org.nr 559113-1825 (”OnDosis” eller ”Bolaget”), kallas härmed till årsstämma tisdagen den 28 juni 2022 kl. 10.00 i Bolagets lokaler på AstraZeneca Bio VentureHub, Pepparedsleden 1 i Mölndal. Insläpp och registrering sker vid AstraZeneca KC entrén kl. 09:45.
The shareholders of OnDosis AB, reg. no. 556582-6558, (“OnDosis” or the “Company”) are hereby given notice of Ann
OnDosis, a Swedish Life science company developing a new device technology platform, announced today that the Company has completed a pre-IPO private placement of SEK 92 million. Investors in the private placement include Aeternum Capital, DIG Investment and Albonja.
The private placement follows the successful expansion of the strategic collaboration between OnDosis and Tiefenbacher
Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine.
Tiefenbacher Group is a pioneering healthcar
Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine
OnDosis, a Swedish Life science company developing a new device technology platform, announced today that the Company has completed a pre-IPO private placement of SEK 92 million. Investors in the private placement include Aeternum Capital, DIG Investment and Albonja.
OnDosis wants to revolutionize the way we take our medicines. The idea is that every single patient, in the easiest possible way, shall get precisely the right amount of medicine and thus lead a better life. Now the company begins a cooperation with Opatus, whose digital tool objectively scales symptoms of ADHD patients. In addition, OnDosis recently received a double recognition at the large
Following the signing of a breakthrough agreement with a leading Business-to-Business Pharma company, AstraZeneca Medtech spin-off OnDosis announces the commitment of a 30 MSEK raise from existing owners and DIG Investment
Following the signing of a breakthrough agreement with a leading Business-to-Business Pharma company, OnDosis announces the commitment of a 30 MSEK raise from existing owners and DIG Investment
Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. The collaboration strengthens both companies’ commitment to further develop and commercialize innovative products within individualized treatments and digital health, combining traditional drug-based medicines, digital therapeutics and intelligent dosing.
Founded as a spin-out from AstraZeneca in 2017, OnDosis is a Swedish start-up addressing one of the major opportunities in healthcare; personalized dosage of medicines. The proprietary technology platform is centered around a connected handheld dosing device that delivers tailored doses of oral medicines. By combining individual dosing of traditional drug-based medicines augmented by digital therapeutics, OnDosis opens a new chapter in personalized medicine where the mission is to improve patients’ life through delivering the perfect dosage; individualized, intuitive, and intelligent.
Pepparedsleden 1
431 50 Mölndal
Sweden